Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability associated with the combination of ATRA/celecoxib/itraconazole as maintenance therapy given after an autologous stem cell transplant in relapsed multiple myeloma patients.


Clinical Trial Description

Primary objective:

To evaluate safety and tolerability associated with the combination of ATRA/ celecoxib/itraconazole given after a salvage transplant for relapsed myeloma in 25 patients in a cycle schedule consisting of three weeks of treatment followed by a rest period of two weeks for a total of five cycles. Subjects will be evaluable only if they have received at least one dose of maintenance treatment. The salvage transplant is not part of this study.

Secondary objective:

To explore changes in frequency and molecular signature in the multiple myeloma stem cell (MMSC) fraction based on flow-cytometric assays and gene expression profiling before and after the experimental treatment and to correlate outcome with expression levels of RARĪ±2 at time of relapse. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02401295
Study type Interventional
Source University of Iowa
Contact
Status Completed
Phase Phase 1
Start date May 2015
Completion date November 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04083534 - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) Phase 1/Phase 2
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Recruiting NCT05577000 - Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01118689 - Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia Phase 1
Withdrawn NCT04802031 - Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma Phase 2
Active, not recruiting NCT00603447 - Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma Phase 1
Active, not recruiting NCT02722668 - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Phase 2
Active, not recruiting NCT04965155 - A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) Phase 2
Completed NCT00592579 - A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma Phase 2
Recruiting NCT06304636 - Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Completed NCT03158688 - Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Phase 3
Completed NCT04434469 - A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma Phase 1
Completed NCT01080391 - Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Phase 3
Completed NCT01949532 - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease Phase 1
Active, not recruiting NCT04398485 - A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Completed NCT01272466 - Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05896228 - Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Phase 2
Terminated NCT04119336 - Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Phase 2
Active, not recruiting NCT05228470 - A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Phase 2